Main menu For students For teachers Explore our subjects Student events & courses

Explore

More for students
Sign in

Teaching Economics

Blog

Unit 3 Micro: Glaxo SmithKline fined $3 billion for off-label marketing

Geoff Riley

3rd July 2012

Share this content:

The scale of the fine is staggering, Glaxo SmithKline has been found guilty of off-label marketing - an illegal strategy - GSK targeted the antidepressant Paxil at patients under age 18 when it was approved only for adults, and promoted the drug Wellbutrin for uses it was not approved for, including weight loss and treatment of sexual dysfunction

This is corporate irresponsibility on a grand scale as this new report makes clear.

Guardian: GlaxoSmithKline fined $3bn for healthcare fraud

Daily Mail: GlaxoSmithKline to pay $3billion fine after pleading guilty to healthcare fraud - the biggest in U.S. history

News video:

See also

Share this content:

Geoff Riley

Geoff Riley FRSA has been teaching Economics for nearly forty years. He has over twenty years experience as Head of Economics at leading schools. He writes extensively and is a contributor and presenter on CPD and Revision conferences in the UK and overseas.

@tutor2uGeoff

You might also like

Ending Peruvian Poverty

8th October 2015

Global Goals are set to address poverty and underdevelopment

6th October 2015

Dissecting the Commodity Price Meltdown

5th October 2015

Uber faces UK regulatory review

2nd October 2015

How do you deal with someone who thinks the Earth is flat?

23rd September 2015

Don't panic - how to end poverty!

23rd September 2015

Teaching PowerPoints for A Level Economics

23rd September 2015

John McDonnell's Economics

16th September 2015